Table 4. Worst haematological WHO grades, by evaluable patient (N=68a) and by evaluable administration of vinorelbine+trastuzumab (N=1705).
|
Patients
|
Administrations
|
||||
|---|---|---|---|---|---|
| Haematological toxicity | Patients (overall incidence) | Grade 3, N (%) | Grade 4, N (%) | Grade 3, N (%) | Grade 4, N (%) |
| Anaemia | 58 (85.3) | 2 (2.9) | — | 3 (0.2) | — |
| Leucopenia | 63 (92.6) | 39 (57.4) | 6 (8.8) | 159 (9.3) | 13 (0.8) |
| Neutropenia | 63 (92.6) | 28 (41.2) | 29 (42.6) | 226 (13.3) | 75 (4.4) |
| Febrile neutropeniab | 2 (2.9) | — | — | — | — |
| Thrombocytopenia | 4 (5.9) | — | — | — | — |
WHO=World Health Organisation.
a
One patient with only one treatment administration was not evaluable for haematological toxicity.
b
One of these patients died of neutropenic sepsis.